MaxCyte CEO Says FDA OK Of IND For Its CAR Receptor Candidate Major Milestone
MaxCyte's first next-generation chimeric antigen receptor MCY-M11 will be studied in solid tumors.
You may also be interested in...
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.